Total Payments
$153,640
2024 Payments
$47,305
Companies
6
Transactions
57
Medicare Patients
4,738
Medicare Billing
$256,781
Payment Breakdown by Category
Consulting$84,603 (55.1%)
Research$62,869 (40.9%)
Travel$4,691 (3.1%)
Food & Beverage$1,477 (1.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $84,603 | 24 | 55.1% |
| Unspecified | $62,869 | 4 | 40.9% |
| Travel and Lodging | $4,691 | 13 | 3.1% |
| Food and Beverage | $1,477 | 16 | 1.0% |
Payments by Type
General
$90,771
53 transactions
Research
$62,869
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CVRx, Inc. | $62,868 | 21 | $0 (2024) |
| Eli Lilly and Company | $54,080 | 24 | $0 (2024) |
| Novo Nordisk Inc | $25,029 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $11,250 | 1 | $0 (2021) |
| Edwards Lifesciences Corporation | $391.67 | 2 | $0 (2024) |
| Lantheus Medical Imaging, Inc. | $21.20 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,305 | 8 | Eli Lilly and Company ($33,599) |
| 2023 | $20,525 | 8 | Novo Nordisk Inc ($11,620) |
| 2022 | $13,907 | 22 | CVRx, Inc. ($7,525) |
| 2021 | $33,120 | 5 | Eli Lilly and Company ($11,720) |
| 2020 | $5,600 | 1 | CVRx, Inc. ($5,600) |
| 2019 | $14,350 | 3 | CVRx, Inc. ($14,350) |
| 2018 | $9,975 | 2 | CVRx, Inc. ($9,975) |
| 2017 | $8,858 | 8 | CVRx, Inc. ($8,858) |
All Payment Transactions
57 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $110.05 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/16/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $11,043.75 | General |
| 10/16/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $1,338.82 | General |
| 10/16/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $449.40 | General |
| 10/16/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $302.54 | General |
| 10/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $274.56 | General |
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $33,599.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 07/20/2024 | Edwards Lifesciences Corporation | — | Food and Beverage | In-kind items and services | $186.48 | General |
| 12/06/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $10,656.25 | General |
| Category: Cardiovascular | ||||||
| 12/06/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $543.06 | General |
| Category: Cardiovascular | ||||||
| 12/06/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $420.82 | General |
| Category: Cardiovascular | ||||||
| 07/29/2023 | Edwards Lifesciences Corporation | — | Food and Beverage | In-kind items and services | $205.19 | General |
| 06/02/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 06/02/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 06/02/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 02/08/2023 | CVRx, Inc. | Barostim Neo System (Device) | — | Cash or cash equivalent | $6,300.00 | Research |
| Category: Heart Failure and Hypertension | ||||||
| 10/11/2022 | CVRx, Inc. | Barostim Neo System (Device) | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/22/2022 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 08/02/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $197.54 | General |
| 08/02/2022 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $188.27 | General |
| 08/02/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $172.13 | General |
| 08/02/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $170.13 | General |
| 08/02/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $170.13 | General |
| 08/02/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $145.00 | General |
| 08/02/2022 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $88.44 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $33,599 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT | Eli Lilly and Company | $11,720 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ENTRESTO RESEARCH | Novartis Pharmaceuticals Corporation | $11,250 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,511 | 1,641 | $1.2M | $71,385 |
| 2022 | 15 | 1,258 | 1,377 | $1.1M | $67,215 |
| 2021 | 13 | 1,045 | 1,174 | $1.0M | $65,071 |
| 2020 | 13 | 924 | 1,015 | $862,185 | $53,111 |
Total Patients
4,738
Total Services
5,207
Medicare Billing
$256,781
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 476 | 484 | $575,960 | $24,059 | 4.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 121 | $42,350 | $10,345 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 104 | 121 | $31,339 | $7,580 | 24.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 52 | 52 | $195,520 | $6,942 | 3.6% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 82 | 84 | $117,348 | $6,607 | 5.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 38 | $19,760 | $4,978 | 25.2% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 82 | 96 | $34,080 | $1,714 | 5.0% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 28 | 28 | $10,836 | $1,637 | 15.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 18 | $7,002 | $1,513 | 21.6% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 105 | 107 | $45,154 | $1,397 | 3.1% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 156 | 157 | $24,335 | $1,333 | 5.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $4,706 | $1,256 | 26.7% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 21 | 21 | $3,255 | $572.88 | 17.6% |
| 76376 | 3d radiographic procedure | Facility | 2023 | 62 | 63 | $3,591 | $453.60 | 12.6% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 45 | 45 | $8,910 | $422.10 | 4.7% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 139 | 145 | $23,925 | $327.60 | 1.4% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 44 | 48 | $10,896 | $247.94 | 2.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 488 | 501 | $596,190 | $25,042 | 4.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 96 | 124 | $30,604 | $7,923 | 25.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 56 | 56 | $210,560 | $7,651 | 3.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 97 | $33,950 | $7,484 | 22.0% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2022 | 67 | 67 | $93,599 | $5,256 | 5.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 21 | $10,920 | $3,136 | 28.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 27 | $9,873 | $2,906 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 17 | 17 | $7,835 | $2,382 | 30.4% |
About Dr. Sheldon Litwin, M.D
Dr. Sheldon Litwin, M.D is a Cardiovascular Disease healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861447989.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sheldon Litwin, M.D has received a total of $153,640 in payments from pharmaceutical and medical device companies, with $47,305 received in 2024. These payments were reported across 57 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($84,603).
As a Medicare-enrolled provider, Litwin has provided services to 4,738 Medicare beneficiaries, totaling 5,207 services with total Medicare billing of $256,781. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease, Internal Medicine
- Location Charleston, SC
- Active Since 05/24/2006
- Last Updated 11/03/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1861447989
Products in Payments
- Barostim Neo System (Device) $62,868
- ENTRESTO (Drug) $11,250
- DEFINITY (Drug) $21.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Charleston
Robert Biederman, Md, MD
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jeffrey Winterfield, M.d, M.D
Cardiovascular Disease — Payments: $549,685
Cardiovascular Disease $549,685
Frank Cuoco, Md, MD
Cardiovascular Disease — Payments: $292,531
Cardiovascular Disease $292,531
Sarah Rinehart, Md, MD
Cardiovascular Disease — Payments: $198,204
Cardiovascular Disease $198,204
Daniel Judge, M.d, M.D
Cardiovascular Disease — Payments: $165,251
Cardiovascular Disease $165,251
Dr. Geetha Pinto, Md, MD
Cardiovascular Disease — Payments: $127,703
Cardiovascular Disease $127,703